BidaskClub cut shares of AxoGen (NASDAQ:AXGN) from a sell rating to a strong sell rating in a research report report published on Thursday, BidAskClub reports.

A number of other research analysts have also commented on the company. BTIG Research lowered their price target on AxoGen to $21.00 and set a buy rating on the stock in a report on Wednesday, August 7th. ValuEngine raised AxoGen from a buy rating to a strong-buy rating in a report on Thursday, August 1st. William Blair lowered AxoGen from an outperform rating to a market perform rating in a report on Wednesday, August 7th. JMP Securities lowered their price target on AxoGen from $43.00 to $28.00 and set an outperform rating on the stock in a report on Wednesday, August 7th. Finally, Cantor Fitzgerald lowered their price target on AxoGen from $30.00 to $21.00 and set an overweight rating on the stock in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $31.00.

AXGN stock traded down $0.01 during mid-day trading on Thursday, reaching $14.28. The company had a trading volume of 16,095 shares, compared to its average volume of 390,184. The stock has a market capitalization of $597.46 million, a P/E ratio of -26.47 and a beta of 0.23. The company has a quick ratio of 7.87, a current ratio of 8.70 and a debt-to-equity ratio of 0.02. AxoGen has a one year low of $11.82 and a one year high of $39.33. The stock’s 50-day simple moving average is $15.99 and its two-hundred day simple moving average is $19.60.

AxoGen (NASDAQ:AXGN) last issued its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.09. The company had revenue of $26.70 million for the quarter, compared to analyst estimates of $26.77 million. AxoGen had a negative return on equity of 16.73% and a negative net margin of 26.91%. The company’s quarterly revenue was up 29.7% compared to the same quarter last year. During the same period last year, the company earned ($0.09) earnings per share. On average, research analysts forecast that AxoGen will post -0.72 EPS for the current fiscal year.

In other news, insider Isabelle Billet bought 5,635 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were purchased at an average cost of $15.11 per share, with a total value of $85,144.85. Following the completion of the acquisition, the insider now directly owns 4,630 shares in the company, valued at $69,959.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CIO Daniel Pietrzak purchased 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 14th. The stock was bought at an average price of $5.65 per share, with a total value of $56,500.00. Over the last ninety days, insiders have purchased 107,535 shares of company stock worth $1,389,672. 6.77% of the stock is owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the stock. Quantamental Technologies LLC boosted its position in shares of AxoGen by 108.3% in the 1st quarter. Quantamental Technologies LLC now owns 1,431 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 744 shares during the period. Cutler Group LP boosted its position in shares of AxoGen by 120.0% in the 1st quarter. Cutler Group LP now owns 2,200 shares of the medical equipment provider’s stock valued at $46,000 after purchasing an additional 1,200 shares during the period. Advisor Group Inc. boosted its position in shares of AxoGen by 86.3% in the 2nd quarter. Advisor Group Inc. now owns 2,548 shares of the medical equipment provider’s stock valued at $51,000 after purchasing an additional 1,180 shares during the period. Stonebridge Capital Advisors LLC acquired a new position in shares of AxoGen in the 2nd quarter valued at $59,000. Finally, Aperio Group LLC acquired a new position in shares of AxoGen in the 2nd quarter valued at $77,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

About AxoGen

AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Featured Story: Stock Portfolio Tracker

Analyst Recommendations for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.